Chiasma Inc.

75 articles about Chiasma Inc.

• Chiasma to Participate in the Jefferies Virtual London Healthcare Conference

  11/16/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows: Dat

• Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update

  11/5/2020

  Chiasma, Inc. announced financial results for the third quarter ended September 30, 2020 and provided an update on its recent phased launch of MYCAPSSA® in the United States as the first and only oral somatostatin analog for the maintenance treatment of people with acromegaly.

• Chiasma to Report Third Quarter 2020 Results on November 5Company to host conference call and webcast at 5:00 p.m. ET

  10/29/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00 pm Eastern Time to discuss financial results for the quarter ended September 30, 2020 and to provide a business update.

• Chiasma Announces Planned Transition of Former CEOMark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer

  10/1/2020

  Chiasma, Inc. announced that Mark Fitzpatrick intends to step down as President and Principal Financial Officer.

• 

  Chiasma’s Octreotide Capsules Could Be Answer to Acromegaly Treatment Burdens

  9/18/2020

  Octreotide, a somatostatin analog, significantly inhibits growth hormone, one of the key drivers of acromegaly.

• Chiasma to Participate in Two September Investor Conferences

  9/8/2020

  - Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that management will be participating in two investor conferences in September. Presentation details: Event: HC Wainwright Virtual 22nd Annual Global Investment Conference Format: Fireside chat Date: Monday,

• Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with AcromegalyChiasma advances U.S. commercial launch originally planned for fourth quarter

  8/31/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the commercial launch and availability of MYCAPSSA® (octreotide) capsules in the United States for patients with acromegaly.

• Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism

  8/17/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the online publication of its CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) Phase 3 clinical tria

• Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness

  8/10/2020

  Chiasma, Inc., a commercial stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2020 and provided a business update.

• Chiasma to Report Second Quarter 2020 Results on August 10Company to host conference call and webcast at 5:00 p.m. ET

  8/3/2020

  Chiasma, Inc., a commercial stage biopharmaceutical company, announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2020 and to provide a business update.

• Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly

  7/27/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced 48-week, open-label efficacy and safety data from the Phase 3 CHIASMA OPTIMAL

• Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants

  7/1/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced the pricing of its previously announced underwritten public offering of 12,500,000

• Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  6/30/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced that it has commenced an underwritten public offering of its common stock,

• Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

  6/26/2020

  MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance treatment in acrome

• 

  FDA Action Alert: Karyopharm, Zogenix, Chiasma, Heron, Intercept and Merck

  6/22/2020

  Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.

• Chiasma To Report First Quarter Financial Results On May 7, 2020

  4/30/2020

  Chiasma, Inc., a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, announced that it will host a conference call and live audio webcast on Thursday, May 7, 2020 at 5:00 p.m.

• Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - April 22, 2020

  4/22/2020

  Chiasma, Inc., a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer.

• 

  Clinical Catch-up for July 22-26

  7/29/2019

  A number of companies reported clinical trial data last week. Here’s a look.

• Chiasma Appoints Roni Mamluk, Ph.D. To Board Of Directors

  6/19/2017

• Chiasma Enforces Job-Cutting Scheme, Axing a Further 44% of Workforce

  8/16/2016